Donated Blood Screening for HIV, HCV and HBV by ID-NAT and the Residual Risk of Iatrogenic Transmission in a Tertiary Care Hospital Blood Bank in Puebla, Mexico.
Humans
Hepatitis B virus
/ genetics
Hepacivirus
/ genetics
Blood Banks
Mexico
/ epidemiology
Tertiary Care Centers
HIV-1
/ genetics
Hepatitis C
/ diagnosis
Blood Donors
HIV Infections
/ diagnosis
Viremia
/ diagnosis
Iatrogenic Disease
Hepatitis B
/ diagnosis
Nucleic Acid Amplification Techniques
/ methods
blood safety
hepatitis B virus
hepatitis C virus
human immunodeficiency virus
residual risk
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
06 06 2023
06 06 2023
Historique:
received:
11
05
2023
revised:
01
06
2023
accepted:
05
06
2023
medline:
29
6
2023
pubmed:
28
6
2023
entrez:
28
6
2023
Statut:
epublish
Résumé
Hepatitis C virus (HCV), human immunodeficiency virus (HIV) and hepatitis B virus (HBV) can be transmitted by blood transfusion. Most transmission occurs during the acute viremic phase (AVP), before antibody development. To reduce transmission risk, individual donor nucleic acid testing (ID-NAT) is used. In Puebla, Mexico, serological tests and ID-NAT have been applied to screen blood donors and detect individuals in AVP. In the present study, 106,125 blood donors' data in two periods (2012-2015 and 2017-2019) were analyzed. The residual risk (RR) values were calculated considering ID-NAT results. The RR for HIV was 14 in 1 million donations or 1 in 71,428, the RR for HVC was 6.8 in 1 million donations or 1 in 147,058 and, for HBV, it was 156 in 1 million donations, or 1 in 6410. Previously, it was predicted that the transmission RR of these viruses would be reduced in Mexico through better screening with NAT. The use of ID-NAT has, indeed, increased the safety of blood reserves for HIV and HCV. However, more research is needed to determine why the residual risk of HBV did not decrease as much over the study period. ID-NAT is an important complementary tool for blood donor screening that should be implemented.
Identifiants
pubmed: 37376630
pii: v15061331
doi: 10.3390/v15061331
pmc: PMC10305412
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Blood Transfus. 2022 Jan;20(1):1-7
pubmed: 34059189
PLoS One. 2021 Feb 19;16(2):e0246704
pubmed: 33606700
Ann Hepatol. 2022 Jan;27 Suppl 1:100579
pubmed: 34793967
Liver Int. 2023 Jun;43(6):1225-1233
pubmed: 37026404
Transfus Med Rev. 2020 Apr;34(2):81-93
pubmed: 32178888
Salud Publica Mex. 2011;53 Suppl 1:S13-8
pubmed: 21877067
Clin Microbiol Rev. 2018 Nov 28;32(1):
pubmed: 30487166
J Med Virol. 2017 Dec;89(12):2149-2157
pubmed: 28792071
PLoS Negl Trop Dis. 2014 Nov 06;8(11):e3158
pubmed: 25375162
Ann Hepatol. 2020 Mar - Apr;19(2):123-125
pubmed: 32138870
Transfusion. 2008 Dec;48(12):2540-8
pubmed: 18680546
Transfusion. 2008 Aug;48(8):1558-66
pubmed: 18466173
Virol J. 2010 Jan 25;7:18
pubmed: 20100349
Transfusion. 2021 May;61(5):1495-1504
pubmed: 33687074
Rev Med Inst Mex Seguro Soc. 2022 Dec 19;60(Suppl 2):96-102
pubmed: 36796006
Transfus Med Hemother. 2019 Apr;46(2):67-75
pubmed: 31191192
Open Forum Infect Dis. 2020 Jul 03;7(8):ofaa272
pubmed: 32875000
Salud Publica Mex. 2020 Mar-Apr;62(2):215-224
pubmed: 32237565
Rev Gastroenterol Mex (Engl Ed). 2021 Oct-Dec;86(4):403-432
pubmed: 34483073
Hum Vaccin Immunother. 2016 Jul 2;12(7):1857-62
pubmed: 27171749
Transfusion. 2010 Jul;50(7):1495-504
pubmed: 20345570
Rev Invest Clin. 2006 Mar-Apr;58(2):101-8
pubmed: 16827262
Pathogens. 2021 Jul 11;10(7):
pubmed: 34358028
J Clin Virol. 2015 Jun;67:73-7
pubmed: 25959163
J Hepatol. 2019 Aug;71(2):397-408
pubmed: 31004683
BMC Infect Dis. 2017 Nov 1;17(Suppl 1):695
pubmed: 29143615
Hepat Mon. 2016 Jun 01;16(6):e36942
pubmed: 27630726
Gac Med Mex. 2014 Sep-Oct;150(5):395-402
pubmed: 25275841
Blood. 2020 Sep 10;136(11):1351-1358
pubmed: 32645148
Transfusion. 2019 Feb;59(2):601-611
pubmed: 30499591